- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Insight Molecular Diagnostics Inc (IMDX)
Track today's live Insight Molecular Diagnostics (IMDX) share price, performance and key data on this page with our current NASDAQ:IMDX stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Insight Molecular Diagnostics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the IMDX share price, head to our technical summary section, which provides analysis on Insight Molecular Diagnostics share price buy/sell indicators using real-time data (or discuss the Insight Molecular Diagnostics (IMDX) stock price today with other investors in the Insight Molecular Diagnostics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:IMDX share price (ISIN: US68235C2061) to enhance your trading decisions with our free investment tools and resources.
What Is the Insight Molecular Diagnostics Inc Share Price Today?
The Insight Molecular Diagnostics share price today is 5.950.
What Is the Stock Symbol for Insight Molecular Diagnostics Inc
The stock symbol (or 'ticker') for Insight Molecular Diagnostics Inc is "IMDX."
What Stock Exchange Does Insight Molecular Diagnostics Inc Trade On?
Insight Molecular Diagnostics Inc is listed and trades on the NASDAQ stock exchange.
Is Insight Molecular Diagnostics Inc a Good Stock to Buy?
Determining whether Insight Molecular Diagnostics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:IMDX share price (ISIN: US68235C2061) to enhance your trading decisions with our free investment tools and resources.
What Is the Insight Molecular Diagnostics Inc Share Price Today?
The Insight Molecular Diagnostics share price today is 5.950.
What Is the Stock Symbol for Insight Molecular Diagnostics Inc
The stock symbol (or 'ticker') for Insight Molecular Diagnostics Inc is "IMDX."
What Stock Exchange Does Insight Molecular Diagnostics Inc Trade On?
Insight Molecular Diagnostics Inc is listed and trades on the NASDAQ stock exchange.
Is Insight Molecular Diagnostics Inc a Good Stock to Buy?
Determining whether Insight Molecular Diagnostics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
5.950
+0.050(+0.85%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.420
6.030
52 wk Range
2.330
8.510
IMDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.4206.030
52 wk Range
2.3308.510
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMDX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
8.333
Upside
+40.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.333
(+40.06% Upside)
Insight Molecular Diagnostics Inc Earnings Call Summary for Q1/2026
- Q1 2026 results met guidance; Q2 revenue projected at $250K with peak cash burn exceeding $9M due to bonuses and FDA submission costs.
- H2 2026 cash burn expected to decline to $6M quarterly, driven by reduced R&D expenses and improved working capital management.
- Company targets $2B addressable market with GraftAssureDx; U.S. orders anticipated later in 2026 following productive FDA engagement.
- Revenue fell 49% YoY to $1.95M over last twelve months, reflecting early-stage commercialization of transplant diagnostics technology.
Last Updated: 20/05/2026, 11:38
Read Full TranscriptEarnings
Latest Release
13/05/2026
EPS / Forecast
-0.12 / -0.65
Revenue / Forecast
32K / --
Compare IMDX to Peers and Sector
Metrics to compare | IMDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −51.1x | −0.4x | |
PEG Ratio | −0.07 | 29.78 | 0.00 | |
Price/Book | −18.0x | −54.1x | 2.6x | |
Price / LTM Sales | 98.6x | 10.3x | 3.0x | |
Upside (Analyst Target) | 52.5% | 32.7% | 53.6% | |
Fair Value Upside | Unlock | −13.1% | 7.6% | Unlock |
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Insight Molecular Diagnostics (NASDAQ: IMDX) Share Price Today?
The Insight Molecular Diagnostics stock price today is 5.950 USD.
What Stock Exchange Does Insight Molecular Diagnostics (IMDX) Trade On?
Insight Molecular Diagnostics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Insight Molecular Diagnostics?
The stock symbol (also called a 'ticker') for Insight Molecular Diagnostics is "IMDX."
What Is the Current Insight Molecular Diagnostics Market Capitalisation?
As of today, Insight Molecular Diagnostics (NASDAQ: IMDX) market cap is 193.580M USD.
What Is Insight Molecular Diagnostics's (IMDX) Earnings Per Share (TTM)?
The Insight Molecular Diagnostics EPS is currently -1.464 (Trailing Twelve Months).
When Is the Next Insight Molecular Diagnostics Earnings Date?
Insight Molecular Diagnostics's next earnings report will be released on 06/08/2026.
Is IMDX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Insight Molecular Diagnostics moving averages and other technical indicators, the daily buy/sell signal for IMDX stock is Strong Buy.
How Many Times Has Insight Molecular Diagnostics Stock Split?
Insight Molecular Diagnostics has split 1 times. (See the IMDX stock split history page for full effective split date and price information.)
How Many Employees Does Insight Molecular Diagnostics Have?
Insight Molecular Diagnostics has 57 employees, based on their latest Companies House report.
What is the current trading status of Insight Molecular Diagnostics (NASDAQ: IMDX)?
As of 01/07/2026, Insight Molecular Diagnostics (IMDX) is trading at a share price of 5.950 USD, with a previous close of 5.900 USD. The stock has fluctuated within a day range of 5.420 USD to 6.030 USD, while its 52-week range spans from 2.330 USD to 8.510 USD.
What Is Insight Molecular Diagnostics (IMDX) Price Target According to Analysts?
The average 12-month price target for Insight Molecular Diagnostics is 8.333 USD, with a high estimate of 12 USD and a low estimate of 4 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.06% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.